Clinical trial, Phase III, randomized, prospective, unicentric, double-blind and placebo-controlled, to estimate the efficacy and safety of intravenous Levosimendan, in the first 24 hours after primary angioplasty, in patients with acute coronary syndrome with ST-segment elevation

Trial Profile

Clinical trial, Phase III, randomized, prospective, unicentric, double-blind and placebo-controlled, to estimate the efficacy and safety of intravenous Levosimendan, in the first 24 hours after primary angioplasty, in patients with acute coronary syndrome with ST-segment elevation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top